Clinical Trials · NCT01744366
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 285
- Start date
- Jan 2013
- Locations
- 29 sites, China
- Primary endpoint
- Cumulative probability of testosterone at castrate level (≤0.5 ng/mL)